A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years

Figures & data

Table 1. Outcome of therapy with dupilumab at week 16, week 24 and week 52.

AD severity scores	Baseline	Week 16	Week 24	Week 52
EASI [SD](Δ %)	32.5 [±2.45]	7.45 [±8.52] (75.5%)	5.77 [±6.73] (82.2%)	3.71 [±4.38] (88.8%)
cDLQI [SD](Δ %)	17.25 [±7.76]	4.32 [±4.92] (74.9%)	3.09 [±4.45] (77.3%)	1.92 [±3.03] (88.8%)
P-NRS [SD](Δ %)	8.38 [±1.66]	3.15 [±2.64] (62.4%)	2.45 [±2.26] (70.7%)	1.76 [±2.14] (78.9%)
S-NRS [SD](Δ %)	7.52 [±2.45]	2.55 [±2.75] (66.0%)	1.71 [±2.15] (77.2%)	1.07 [±2.01] (85.7%)

EASI: Eczema Area and Severity Index; cDLQI: Children Dermatology Life Quality Index; P-NRS: Pruritus-Numerical Rating Scale; S-NRS: Sleep-Numerical Rating Scale; Δ %: mean percentage reduction from baseline to each timepoint.

Table 2. Demographic and clinical characteristics of the patient population (n =96).

Characteristic	Value
Age, mean (SD), years	8.22 (3.96)
Female, no. (%)	46 (48)
Male, no. (%)	50 (52)
BMI, mean (SD)	18.82 (5.65)
Duration of AD, mean (SD), years	7.15 (5.08)
Family atopic history, no. (%)	58 (60.4)
Patients with ≥1 concurrent atopic comorbidity, no. (%)	50 (52)
Asthma	32 (33.3)
Rhinitis	44 (45.8)
Food allergies	6 (6.25)
Conjunctivitis	12 (12.5)
Clinical phenotype, no. (%)
Flexural dermatitis                  40 (41.7)
Generalized eczema                 38 (39.6)
Nummular eczema                     8 (8.3)
Head and neck dermatitis                   2 (2.1)
Prurigo nodularis                       1 (1.04)
Hands eczema                     1 (1.04)
Erythroderma                     1 (1.04)
Concomitant flexural AD and hands eczema         5 (5.21)
Previous treatments, no. (%)
Topical corticosteroids	80 (83.3)
Topical calcineurin inhibitors	33 (34.4)
Phototherapy (nb-UVB)	12 (12.5)
Systemic corticosteroids	58 (60.4)
Cyclosporine A	16 (16.7)
Omalizumab	2 (2.1)
Methotrexate	4 (4.2)

SD: standard deviation; BMI: body mass index; AD: atopic dermatitis; nb-UVB: narrow band ultraviolet B.

Figure 1. Flow diagram showing number of patients screened, included and dropouts.

Figure 2. Outcome at week 16, week 24, and week 52 of therapy with dupilumab in 91 Childrem 6-11 years of age with moderate-to-severe atopic dermatitis.

EASI: Eczema Area and Severity Index; S-NRS: Sleep Numerical Rating Scale; P-NRS: Pruritus Numerical Rating Scale; c-DLQI: Children’s Dermatology Life Quality Index; W: week of dupilumab treatment; ***p < 0.0001; **p < 0.001; *p < 0.005; ns: not significant.

Data availability statement

Data are reported in the current study.